262 related articles for article (PubMed ID: 18272489)
21. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.
Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794
[TBL] [Abstract][Full Text] [Related]
22. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
23. Somatodendritic Kv7/KCNQ/M channels control interspike interval in hippocampal interneurons.
Lawrence JJ; Saraga F; Churchill JF; Statland JM; Travis KE; Skinner FK; McBain CJ
J Neurosci; 2006 Nov; 26(47):12325-38. PubMed ID: 17122058
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
25. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
26. KCNQ/M-channels regulate mouse vagal bronchopulmonary C-fiber excitability and cough sensitivity.
Sun H; Lin AH; Ru F; Patil MJ; Meeker S; Lee LY; Undem BJ
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30721152
[TBL] [Abstract][Full Text] [Related]
27. Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm.
Mani BK; O'Dowd J; Kumar L; Brueggemann LI; Ross M; Byron KL
J Cardiovasc Pharmacol; 2013 Jan; 61(1):51-62. PubMed ID: 23107868
[TBL] [Abstract][Full Text] [Related]
28. Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs.
Li T; Wu K; Yue Z; Wang Y; Zhang F; Shen H
Mol Cell; 2021 Jan; 81(1):25-37.e4. PubMed ID: 33238160
[TBL] [Abstract][Full Text] [Related]
29. KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.
Varghese N; Lauritano A; Taglialatela M; Tzingounis AV
J Neurophysiol; 2021 Apr; 125(4):1440-1449. PubMed ID: 33729829
[TBL] [Abstract][Full Text] [Related]
30. M-channels (Kv7/KCNQ channels) that regulate synaptic integration, excitability, and spike pattern of CA1 pyramidal cells are located in the perisomatic region.
Hu H; Vervaeke K; Storm JF
J Neurosci; 2007 Feb; 27(8):1853-67. PubMed ID: 17314282
[TBL] [Abstract][Full Text] [Related]
31. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
Wickenden AD; Yu W; Zou A; Jegla T; Wagoner PK
Mol Pharmacol; 2000 Sep; 58(3):591-600. PubMed ID: 10953053
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
Qi J; Zhang F; Mi Y; Fu Y; Xu W; Zhang D; Wu Y; Du X; Jia Q; Wang K; Zhang H
Eur J Med Chem; 2011 Mar; 46(3):934-43. PubMed ID: 21296466
[TBL] [Abstract][Full Text] [Related]
33. Functional analysis of potassium channels in Kv7.2 G271V mutant causing early onset familial epilepsy.
Wang J; Li Y; Hui Z; Cao M; Shi R; Zhang W; Geng L; Zhou X
Brain Res; 2015 Aug; 1616():112-22. PubMed ID: 25960349
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators.
Kumar M; Reed N; Liu R; Aizenman E; Wipf P; Tzounopoulos T
Mol Pharmacol; 2016 Jun; 89(6):667-77. PubMed ID: 27005699
[TBL] [Abstract][Full Text] [Related]
35. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
36. Pore- and voltage sensor-targeted KCNQ openers have distinct state-dependent actions.
Wang CK; Lamothe SM; Wang AW; Yang RY; Kurata HT
J Gen Physiol; 2018 Dec; 150(12):1722-1734. PubMed ID: 30373787
[TBL] [Abstract][Full Text] [Related]
37. Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
Xu W; Wu Y; Bi Y; Tan L; Gan Y; Wang K
Mol Pain; 2010 Aug; 6():49. PubMed ID: 20796319
[TBL] [Abstract][Full Text] [Related]
38. Desensitization of chemical activation by auxiliary subunits: convergence of molecular determinants critical for augmenting KCNQ1 potassium channels.
Gao Z; Xiong Q; Sun H; Li M
J Biol Chem; 2008 Aug; 283(33):22649-58. PubMed ID: 18490447
[TBL] [Abstract][Full Text] [Related]
39. Potential role of KCNQ/M-channels in regulating neuronal differentiation in mouse hippocampal and embryonic stem cell-derived neuronal cultures.
Zhou X; Song M; Chen D; Wei L; Yu SP
Exp Neurol; 2011 Jun; 229(2):471-83. PubMed ID: 21466805
[TBL] [Abstract][Full Text] [Related]
40. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels.
Soh H; Tzingounis AV
Mol Pharmacol; 2010 Dec; 78(6):1088-95. PubMed ID: 20843955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
